Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marpai, Inc. filings document material events, capital-structure matters and operating disclosures for a healthcare technology company whose Class A common stock trades on the OTCQX Market under MRAI. Recent Form 8-K reports cover results of operations, material definitive agreements and governance matters.
The filing record includes disclosures on promissory-note financing for working capital, amendments to note terms, officer appointments, and charter changes authorizing blank-check preferred stock. Marpai filings also identify its registered Class A common stock, emerging growth company status in certain reports, and formal risk and compliance references tied to its public-company reporting obligations.
Marpai, Inc. director Eitan Yaron reported equity compensation changes involving Class A Common Stock. On May 29, 2026, he acquired 175,000 shares at $0.00 per share as a grant or award, bringing his direct holdings to 1,224,073 shares.
A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, described as a forfeiture of unvested restricted stock units under the award terms. The new RSUs were granted under Marpai, Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date, indicating compensation-related, non‑market activity.
Marpai, Inc. Chief Financial Officer Steve Andrew Johnson reported acquiring more Class A Common Stock. He made an open-market purchase of 1,100 shares at $0.62 per share and also received a grant of 125,000 restricted stock units under the company’s 2024 Global Stock Incentive Plan, which were fully vested on issuance. Following these transactions, he holds 1,024,192 shares directly, indicating a routine increase in his equity stake through both personal buying and equity compensation.
Marpai, Inc. director Shiv Sagiv reported stock-based compensation and a prior forfeiture involving Class A Common Stock. On May 29, 2026, he acquired 125,000 shares at $0.00 per share through a grant of fully vested restricted stock units under the 2024 Global Stock Incentive Plan. A prior December 8, 2025 entry shows a 50,000-share disposition to the issuer tied to the forfeiture of unvested RSUs. After these transactions, Sagiv directly holds 613,667 shares, and no derivative securities remain reported in this filing.
Marpai, Inc. director Robert M. Pons reported equity compensation and a prior forfeiture involving Class A Common Stock–linked awards. On May 29, 2026, he acquired 100,000 shares at a stated price of $0.00 per share as a grant or award. Footnotes explain these restricted stock units were granted under Marpai Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, representing the forfeiture of unvested RSUs under the award terms. Following the reported transactions, Pons directly holds 484,200 shares of Class A Common Stock.
Marpai, Inc. director Jennifer Rosario Calabrese reported equity compensation changes in Class A common stock. On May 29, 2026, she acquired 100,000 shares at a stated price of $0.00 per share, reflecting a fully vested restricted stock unit award granted under Marpai Inc.'s 2024 Global Stock Incentive Plan. The filing also notes a December 8, 2025 forfeiture of 50,000 unvested RSUs returned to the issuer pursuant to the award terms. Following these transactions, she directly holds 225,000 shares of Class A common stock.
Lamendola Damien reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. reported that Chief Executive Officer Damien Lamendola received a grant of 300,000 shares of Class A common stock on May 29, 2026 at $0.00 per share. The shares were granted as restricted stock units under the 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. Following the grant, he directly owns 1,650,000 Class A shares, with additional indirect holdings through entities he controls, including HillCour Investment Fund, LLC and WellEnterprises USA, LLC.
DiClaudio Colleen reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Colleen DiClaudio received 125,000 shares of Class A Common Stock as a fully vested equity award. The grant was made at a price of $0.00 per share under Marpai, Inc.'s 2024 Global Stock Incentive Plan and is deemed fully vested on the issuance date.
After this grant, DiClaudio directly holds a total of 267,500 shares of Class A Common Stock. This is a compensation-related stock award rather than an open-market purchase, so it reflects board-level equity compensation rather than a trading decision.
Marpai, Inc. director Eitan Yaron reported an open-market purchase of Class A Common Stock. On May 20, 2026, he bought 10,000 shares at a price of $0.27 per share. After this transaction, he directly holds 1,099,073 shares of Marpai stock.
Marpai, Inc. reported a Q1 2026 net loss of $3.2M on revenue of $4.4M, with revenue down about 18% from Q1 2025 as customer turnover reduced volume. Operating loss was $2.5M and net loss per share improved to $0.13 due to a higher share count.
The balance sheet remains highly leveraged, with total liabilities of $46.2M against assets of $10.9M, resulting in stockholders’ deficit of $35.2M. Unrestricted cash was only $0.2M, while short‑term debt was about $10.3M and long‑term debt about $18.6M, including $8.3M of senior secured convertible debentures and $19.9M owed to AXA.
Operating cash flow was negative $0.5M. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital or asset sales. Marpai has extended the maturity of its debentures to April 2028, taken related‑party loans from its CEO, and is exploring strategic alternatives, including potential financings, business combinations, or a sale.
Marpai, Inc. entered into an Amendment Agreement with its Chief Executive Officer, Damien Lamendola, to extend the maturity dates of two existing promissory notes he holds. The notes have principal amounts of $410,000 and $250,000, each bearing interest at 12% per annum. Their maturities were previously April 11, 2026 and May 10, 2026, and have now been extended to September 1, 2026 for all outstanding principal and interest. All other terms and conditions of the notes remain unchanged.